Snapshot
Abbott Laboratories reported $11.16B of revenue in Q1 2026, up 7.8% year over year, with diluted EPS of $0.61 and an operating margin of 12.0%.
- Revenue
- $11.16B
- YoY growth
- +7.8%
- Diluted EPS
- $0.61
- Operating margin
- 12.0%
$11.16B
Revenue
+7.8%
YoY growth
$0.61
Diluted EPS
12.0%
Operating margin
01 Key takeaways
What management said
- •These non-GAAP financial measures are reconciled with the comparable GAAP financial measures in our earnings news release and regulatory filings from today, which are available on our website at abbott.com.
- •This quarter also marked an important strategic milestone for Abbott with the completion of our acquisition of Exact Sciences.
- •This acquisition adds a new high-growth business to the Abbott portfolio, further strengthening our leadership position in diagnostics and expanding our presence into one of the fastest-growing areas of healthcare, cancer diagnostics.
- •As we communicated at the time of the acquisition announcement, we forecast the addition of Exact Sciences to add approximately $3 billion of incremental sales in 2026 and accelerate Abbott's long-term sales growth rate.
- •Growth of 3% was driven by growth in the U.S., Europe, and Latin America.
- •In our rapid and molecular diagnostics business, sales declined 10%, reflecting lower demand for respiratory virus testing due to a much weaker respiratory season compared to last year.
- •In cancer diagnostics, sales grew 13% on a comparable basis, driven by mid-teens growth of Cologuard and high teens growth in international markets.
- •While we are still early in the transition back toward a more sustainable balance between price and volume-driven growth, I am encouraged by the progress we're making.
- •Early data indicates we are seeing the intended effect, with volume growth beginning to follow our pricing actions.
- •We continue to expect that these pricing actions, combined with the launch of several new products, will result in growth improving over the course of the year.
- •Growth was broad-based across the markets we serve, which included double-digit growth in several countries across Latin America and Asia Pacific regions.
- •Demand in these markets continues to be supported by favorable long-term healthcare, economic, and demographic trends.
SourcesCompany financials · earnings call
Last updated